Microfluidics meets 3D cancer cell migration

Mehta, Pranav; Rahman, Zaid; Dijke, Peter ten; Boukany, Pouyan E.

doi:10.1016/j.trecan.2022.03.006

Cited by 30 publications

(28 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It leads to the failure of tumor detection in these cultures (e.g., MDA-MB-231 breast cancer cell lines). To resolve these problems, OoC provides more complex tissue-based culture models that replicate key characteristics missed in conventional monolayer or spheroid cultures by combing 3D culture model with microfluidics ( Figure 3 B) [ 98 ]. For instance, a model of breast cancer invasion has been successfully constructed by combing 3D microfluidics and spheroid culture.…”

Section: Manufacture Methodologiesmentioning

confidence: 99%

Recent Advances of Organ-on-a-Chip in Cancer Modeling Research

Liu

Zhang

et al. 2022

Biosensors

View full text Add to dashboard Cite

Although many studies have focused on oncology and therapeutics in cancer, cancer remains one of the leading causes of death worldwide. Due to the unclear molecular mechanism and complex in vivo microenvironment of tumors, it is challenging to reveal the nature of cancer and develop effective therapeutics. Therefore, the development of new methods to explore the role of heterogeneous TME in individual patients’ cancer drug response is urgently needed and critical for the effective therapeutic management of cancer. The organ-on-chip (OoC) platform, which integrates the technology of 3D cell culture, tissue engineering, and microfluidics, is emerging as a new method to simulate the critical structures of the in vivo tumor microenvironment and functional characteristics. It overcomes the failure of traditional 2D/3D cell culture models and preclinical animal models to completely replicate the complex TME of human tumors. As a brand-new technology, OoC is of great significance for the realization of personalized treatment and the development of new drugs. This review discusses the recent advances of OoC in cancer biology studies. It focuses on the design principles of OoC devices and associated applications in cancer modeling. The challenges for the future development of this field are also summarized in this review. This review displays the broad applications of OoC technique and has reference value for oncology development.

show abstract

Section: Manufacture Methodologiesmentioning

confidence: 99%

Recent Advances of Organ-on-a-Chip in Cancer Modeling Research

Liu

Zhang

et al. 2022

Biosensors

View full text Add to dashboard Cite

show abstract

“…Microfluidic devices offer attractive conditions such as low Reynolds numbers, reduced sample volume, the ability to perform multiple assays on a single chip, fast reaction time, control of conditions, portability, and point-of-care application, and could be utilized in laboratory tests of blood, urine, or any fluid [ 153 ]. The chemical properties of the reservoirs providing a suitable platform for biological samples are vital for biomedical applications of microfluidic systems.…”

Section: Emerging Technologiesmentioning

confidence: 99%

Review on Bortezomib Resistance in Multiple Myeloma and Potential Role of Emerging Technologies

et al. 2023

View full text Add to dashboard Cite

Multiple myeloma is a hematological cancer type. For its treatment, Bortezomib has been widely used. However, drug resistance to this effective chemotherapeutic has been developed for various reasons. 2D cell cultures and animal models have failed to understand the MM disease and Bortezomib resistance. It is therefore essential to utilize new technologies to reveal a complete molecular profile of the disease. In this review, we in-depth examined the possible molecular mechanisms that cause Bortezomib resistance and specifically addressed MM and Bortezomib resistance. Moreover, we also included the use of nanoparticles, 3D culture methods, microfluidics, and organ-on-chip devices in multiple myeloma. We also discussed whether the emerging technology offers the necessary tools to understand and prevent Bortezomib resistance in multiple myeloma. Despite the ongoing research activities on MM, the related studies cannot provide a complete summary of MM. Nanoparticle and 3D culturing have been frequently used to understand MM disease and Bortezomib resistance. However, the number of microfluidic devices for this application is insufficient. By combining siRNA/miRNA technologies with microfluidic devices, a complete molecular genetic profile of MM disease could be revealed. Microfluidic chips should be used clinically in personal therapy and point-of-care applications. At least with Bortezomib microneedles, it could be ensured that MM patients can go through the treatment process more painlessly. This way, MM can be switched to the curable cancer type list, and Bortezomib can be targeted for its treatment with fewer side effects.

show abstract

“…The tumor-on-a-chip model however, was designed to overcome these limitations ( Barros et al, 2021 ). These microfluidic models of lung tumors are often derived from established lung cancer cell lines, which form a spheroid in the microchannel, adding a further 3D aspect to these studies ( Mehta et al, 2022 ). Microfluidic devices have been used to study drug resistance, the efficiency of photodynamic therapy, the influence of mechanical forces in the lungs on tumor progression and drug resistance, and characterization of cell-cell communication in the tumor microenvironment ( Del Piccolo et al, 2021 ).…”

Section: The Application Of Lung Organoidsmentioning

confidence: 99%

Lung Organoids—The Ultimate Tool to Dissect Pulmonary Diseases?

Bosáková

Zuani

Sládková

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Organoids are complex multicellular three-dimensional (3D) in vitro models that are designed to allow accurate studies of the molecular processes and pathologies of human organs. Organoids can be derived from a variety of cell types, such as human primary progenitor cells, pluripotent stem cells, or tumor-derived cells and can be co-cultured with immune or microbial cells to further mimic the tissue niche. Here, we focus on the development of 3D lung organoids and their use as disease models and drug screening tools. We introduce the various experimental approaches used to model complex human diseases and analyze their advantages and disadvantages. We also discuss validation of the organoids and their physiological relevance to the study of lung diseases. Furthermore, we summarize the current use of lung organoids as models of host-pathogen interactions and human lung diseases such as cystic fibrosis, chronic obstructive pulmonary disease, or SARS-CoV-2 infection. Moreover, we discuss the use of lung organoids derived from tumor cells as lung cancer models and their application in personalized cancer medicine research. Finally, we outline the future of research in the field of human induced pluripotent stem cell-derived organoids.

show abstract

Microfluidics meets 3D cancer cell migration

Cited by 30 publications

References 91 publications

Recent Advances of Organ-on-a-Chip in Cancer Modeling Research

Recent Advances of Organ-on-a-Chip in Cancer Modeling Research

Review on Bortezomib Resistance in Multiple Myeloma and Potential Role of Emerging Technologies

Lung Organoids—The Ultimate Tool to Dissect Pulmonary Diseases?

Contact Info

Product

Resources

About